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Abstract:  This review explores the processes underlying  the deleterious effects  of the 
presence of insoluble or colloidal depositions within the central nervous system. These 
materials are chemically unreactive and can have a prolonged residence in the brain. They 
can be composed of mineral or proteinaceous materials of intrinsic or exogenous origin. 
Such  nanoparticulates  and  colloids  are  associated  with  a  range  of  slow-progressing 
neurodegenerative  states.  The  potential  common  basis  of  toxicity  of  these  materials  is 
discussed.  A  shared  feature  of  these  disorders  involves  the  appearance  of  deleterious 
inflammatory changes in the CNS. This may be due to extended and ineffective immune 
responses.  Another  aspect  is  the  presence  of  excess  levels  of  reactive  oxygen  species 
within the brain. In addition with their induction by inflammatory events, these may be 
further heightened by the presence of redox active transition metals to the large surface 
area afforded by nanoparticles and amphipathic micelles. 
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1. Inflammation is Elevated during Brain Aging 
Excess  levels  of  inflammation  characterize  the  aged  brain  [1].  Even  in  the  absence  of  clearly 
identifiable stimuli, the immune system of the senescent brain is chronically activated. Microglial cells 
are increasingly activated with aging [2,3]. The cause of this unfruitful activity is uncertain, but may 
be related to the finding that, after an immune reaction has been provoked in the brain, the response is 
OPEN ACCESS Int. J. Environ. Res. Public Health 2011, 8                 
 
2201 
more pronounced, and takes much longer to dissipate and return to basal levels than is the case with 
other tissues [4,5]. Thus the aged brain may be a historical repository of immune memory reflecting 
activating events that abated long ago. 
While there is evidence of heightened inflammation in the aged brain, these changes are further 
augmented  in  many  age-related  or  neurological  diseases.  These  include  Alzheimer’s  disease  [6], 
Parkinson’s disease [7], Huntington’s disease [8]. Other neurological disorders less clearly associated 
with senescence, that characteristically express neuroinflammatory changes include; the human variant 
of Bovine Spongy Encephalopathy and other prion diseases [9,10], and Down’s syndrome [11]. All of 
these  involve  the  deposition  of  long-lived  insoluble  protein  aggregates  within  the  brain.  Such 
intracellular proteinaceous inclusions may be constituted of misfolded proteins that are not readily 
guided  into  degradation  by  ubiquitin-driven  proteolytic  processes  [12]  and  this  can  lead  to  their 
identification  as  non-self  and  thus  cause  prolonged  activation  of  the  innate  immune  system  [13]. 
Failure of the heat shock proteins to act as effective chaperones and ensure proper folding, transport 
and clearance of such proteins, can lead to protein accretion and thence to microglial activation [14,15]. 
In a parallel manner, impaired phagocytic clearance of extracellular aggregates by microglia, can also 
lead to enduring inflammation [16]. Microglia are resident innate immune cells in the CNS and thus 
key components of the immune response. They are activated by several means, notably the Toll-like 
receptor  (TLR)  system  and  MAP  kinases.  TLR  signaling  also  mediates  the  beneficial  effects  of 
microglial activation but the extended release of inflammatory signals can provoke damage associated 
with  the  development  of  neurodegenerative  diseases.  The  functional  outcome  of  TLR-induced 
activation of microglia in the CNS then depends on a subtle balance between protective and harmful 
effects [17]. Cytokines such as interleukins IL-1, IL-6 & IL-8 are primarily synthesized by activated 
microglia in the brain in response to pathogens and trauma. Prolonged production of these peptides can 
result  in  cytotoxicity  because  they  recruit  and  activate  macrophages  that  can  produce  high 
concentrations of reactive oxygen species. Several species of inflammatory cytokine are elevated in the 
brain in Alzheimer’s disease [18]. In an animal model of chronic inflammation, induced by infusion of 
lipopolysaccharide, there was astrogliosis as well as an increase in the levels of amyloid-β protein 
precursor (AβPP), IL-1, and TNF mRNA levels. This was subsequently followed by hippocampal 
cell loss and impairment of spatial memory, all of which mirror changes seen in the Alzheimer’s 
disease brain [19]. This suggests that inflammation can cause some of the signs of Alzheimer’s disease 
rather than being merely an epiphenomenon.  
The  animals  generally  used  as  models  in  which  to  study  brain  aging  are  generally  rodents  or 
monkeys, neither of which normally present with Alzheimer’s or Parkinson’s diseases. Attempts have 
been  made  to  overcome  this  by  insertion  of  human  genes  associated  with  these  diseases.  Such 
transgenic disease models can partially express neurological deficits and neuropathology relating to 
these diseases. 
The natural drift toward a high basal levels of immune activation found with progressive maturation 
can thus be further driven in a wide range of brain disorders. When mice subjected to a systemic 
inflammatory stimulus such as lipopolysaccharide (LPS) or tumor necrosis factor alpha (TNFα), levels 
of inflammatory cytokines are transiently elevated in serum and liver and these return to basal levels 
within 1 week. On the other hand, after LPS treatment such cytokines are elevated in central nervous 
tissue for over 10 months, a considerable fraction of the mouse lifespan. This is associated with both Int. J. Environ. Res. Public Health 2011, 8                 
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microglial activation and continuing neuronal death [20]. These findings give clues as to why the aged 
brain  shows  evidence  of  continuing  inflammation.  Earlier  inflammatory  events  such  as  infections 
involving the whole body may be effectively remembered in the CNS. Thus inflammation can be a 
self-propelling  mechanism  of  progressive  neurodegeneration.  This  would  account  for  the  fact  that 
many age-related neurological diseases are associated with even high levels of inflammation than 
those associated with normal brain aging. 
Many neurological diseases are specifically associated with the aging process and are not found in 
younger animals. Since many of these are idiopathic and not of clear genetic origin it is likely that a 
host  of  environmental  factors,  by  interacting  with  brain  senescence,  can  initiate  or  promote  the 
progression  of  distinct  neurodegenerative  disorders.  An  extended  period  of  pronounced  brain 
inflammation is directly able to damage brain structures and impair behavioral function.  
2. The Aggregation of Intrinsic Protein Species within Nervous Tissue 
There is considerable evidence that the presence of particulate materials within and around neurons 
can  activate  glial  surveillance  mechanisms.  If  these  materials  are  irresolvable,  this  can  lead  to 
continued exacerbation of inflammatory responses. Many neurodegenerative diseases are associated 
with the extended presence of proteinaceous materials that cannot readily be removed by proteolytic 
enzymes. The indigestiblity of some of these may be due to their adopting the resistant β-pleating 
configuration. This is true of both β-amyloid within plaques and the hyperphosphorylated tau protein 
forming neurofibrillary tangles found in Alzheimer’s disease [21,22], aberrant prion protein found in 
bovine spongy encephalomyelitis [23], and β-synuclein inclusions found in Parkinson’s disease [24] as 
well as the mutant huntingtin protein found in Huntington’s Disease [25]. Table 1 is an incomplete 
listing  of  the  aggregates  and  their  constituent  proteins,  associated  with  various  neurodegenerative 
conditions. Such beta-pleated proteins can be considered misfolded, and although they can lead to 
microglial  activation  [26,27],  their  structure  does  not  allow  them  to  be  dispersed  by  heat  shock 
proteins  and  the  ubitiquitin-proteosome  system.  The  constituent  proteins  of  persistent  protein 
aggregates  found  in  neurological  disease,  are  often  highly  ubiquitinylated  suggesting  ineffective 
attempts  at  degradation.  However  there  is  evidence  of  limited  clearance  of  Alzheimer-associated 
amyloid  plaques  by  autophagic  means  [28].  There  is  also  the  suggestion  that  under  some 
circumstances, aggregate formation represents an effective defensive strategy [29]. 
Amyloid-β  (Aβ)  is  cleaved  from  APP  and  can  act  in  a  cytokine-like  manner  and  promote 
inflammatory events. For example, Aβ activates microglia causing them to act as phagocytes [30]. 
Such  reactive  glial  cells  not  only  increase  nitric  oxide  production  [31],  but  they  also  activate 
complement proteins, which are a key component of the inflammatory cascade [32]. Analogous to the 
function of interleukins, the secretion of Aβ may be an integral part of an attempted innate immune 
response of the CNS against pathological processes. If the provocative stimulus remains unresolved, 
the extended production of materials which may have beneficial value in the short term can have 
deleterious consequences and lead to neurodegeneration.  
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Table1. Proteinaceous inclusions associated with specific neurological diseases. 
Neurodegenerative disorder  Accumulating particles 
Protein associated with 
insoluble material 
Alzheimer’s disease 
Amyloid plaques, 
neurofibrillary tangles 
β-amyloid peptides, 
Hyperphosphoylated tau  
Dementia with Lewy Bodies (DLB)  Lewy bodies   
Parkinson’s disease  Lewy bodies  α-synuclein 
Huntington’s disease  Intranuclear inclusions 
huntingtin protein with  
expanded glutamine repeats 
Spinocerebellar ataxia type 3  Intranuclear inclusion 
ataxin-3 with expanded  
glutamine repeats 
Down’s syndrome  Lewy bodies, amyloid plaques  α-synuclein, β-amyloid 
Human variant of Bovine spongy 
encephalopathy, Creutzfeldt-Jakob disease 
Amyloid plaques  Prion protein variant 
Pick’s disease  Pick bodies  Hyperphosphorylated tau 
Prion protein (PrP) is a transmembrane glycoprotein that is constitutively expressed in both glial 
and neuronal cells. The misfolding and consequent aggregation of the aberrant variant of the protein 
(PrPsc) is thought to be responsible for spongiform encephalopathies (prion diseases) such as bovine 
spongy encephalopathy, Gerstmann-Strä ussler-Scheinker’s syndrome and Creutzfeldt-Jakob disease. 
These are characterized by the extracellular deposition of the pathological form of the PrP protein 
accompanied by neuroinflammation, amyloid plaques, gliosis, vacuole formation and neuronal cell 
death [33,34]. Although its function is unknown, the normal prion protein (PrPc) incorporates copper 
and  has  superoxide  dismutase  activity  [35].  PrPc  binds  copper  at  its  N-terminal  region  and  
PrPc-deficient mice have evidence of increased levels of oxidative stress [36]. Thus, the normal form 
of this protein may play a role in protecting cells from oxidative damage and some of the pathology 
associated with PrPsc may be related to its inability to sequester copper adequately. 
Inclusions within the brain, whether intracellular or extracellular, are frequently associated with 
evidence of generation of excess amounts of oxidant free radicals and immune activation. There is 
good temporal evidence to suggest a causal relation between failure to remove such inclusions and the 
appearance  of  these  undesirable  events.  While  each  indigestible  proteinaceous  aggregate  has  a 
distinctive origin and composition, they all seem to trigger a similar extended immune response. 
3. Non-Protein Xenobiotic Colloids and Nanoparticles 
Other classes of particle of exogenous origin can deposit in the brain and are poorly cleared. These 
can promote cerebral inflammation and pro-oxidant changes in a manner analogous to the responses 
generated by aggregates of endogenous origin described above. These xenobiotic compounds (Table 2) 
include  colloids  and  nanoparticles  composed  of  inorganic  materials.  Inhaled  mineral  and  organic 
particulates have been shown to be able to access the brain and this may occur substantially by way of 
the olfactory epithelium [37-39]. Many studies on the effects of air pollution on CNS disease report 
effects of inhaled particles in conjunction with gases, a combination typical of combustion products 
such as diesel fumes [40]. These complex mixtures while societally relevant will not be discussed here. 
However, even when particles are isolated from gaseous constituents of smoke, they can provoke an Int. J. Environ. Res. Public Health 2011, 8                 
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inflammatory response in brain tissues [41,42]. Several types of metal particles are known to initiate or 
potentiate neuroinflammation. Nanosized titanium particles can exaggerate the normal brain response 
to an inflammogen such as lipopolysaccharide and effect microglial activation [43]. Silver, iron oxide 
and manganese oxide nanoparticles may act similarly [38,44]. Even elemental carbon particles can be 
neuroinflammatory [45]. In addition to causing damage to neurons, an inflammatory focus induced by 
metallic  nanoparticles  near  cerebral  blood  microvessels  can  increase  the  permeability  of  capillary 
endothelium and disrupt normal function of the blood brain barrier [46]. Although less than 0.1% of 
inhaled or systemically injected nanoparticles are found within the brain, they are able to enter glia and 
neurons and inhibit neuronal firing [47]. 
The exact crystalline structure of such particles and their size may be critical in determining the 
extent of their neurotoxicity [41,48]. Aluminum salts, which are present in colloidal form at neutral pH, 
are also able to elevate pro-inflammatory markers both in isolated systems and in brains of intact 
animals [49-51]. Aluminum suspensions in drinking water at levels resembling those found in some 
residential water supplies, can elevate indices of inflammation and oxidative stress in the brain [52,53]. 
Table  2.  Particles  and  colloids  of  exogenous  origin  causing  an  inflammatory  response 
within the CNS. 
Particle origin  Particle constituents  Reference 
Combustion products in polluted air  Organic chemicals, minerals   40,42 
Combustion products in polluted air  Elemental carbon  45 
Disinfection, water treatment  Silver oxide  46 
Welding and mining operations  Manganese oxide  38 
Medical diagnosis, therapy  Titanium oxide  43,44 
Drinking water  Colloidal aluminum salts  51,52 
A common feature of all such foreign materials may be their ability to attract glia to their location 
and, since they cannot be digested by proteolytic processes, the resulting attempted phagocytic activity 
is essentially ineffective. The deleterious effects of a prolonged and ineffective immune response is 
well illustrated in the case of lung silicosis where the persistent presence of mineral particles leads to a 
futile phagocytic attack by alveolar macrophages on such irresolvable foci, which ultimately leads to 
severe pathological changes involving inflammatory cytokines [54]. Silicosis can progress long after 
the cessation of exposure to the original xenobiotic stimulus. This may be comparable to the situation 
in the CNS when the attempted clearance of particulate matter fails. Such failure can lead to cell death 
and further recruitment of cells involved in the generation of inflammatory responses. 
4. The Role of Transition Metals in Nanoparticle and Aggregate Neurotoxicity 
The mechanisms by which relatively inert nanoparticles and colloids form a focus of irritation may 
involve their large surface area and the materials, which can be attracted to such surfaces. Copper, iron 
and manganese are essential metals, toxic to cells in the free form and thus generally well sequestered 
in tissues by their binding to specific proteins such as ferritin and ceruloplasmin. These metals are able 
to undergo valence changes under normal physiological conditions and this redox flux is associated 
with generation of damaging short-lived pro-oxidant species.  Int. J. Environ. Res. Public Health 2011, 8                 
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Levels of copper, zinc and iron are increased on the surface of Alzheimer’s disease senile plaques 
and the presence of these redox reactive metals in both plaques and neurofibrillary tangles induces 
hydrogen peroxide-dependent oxidation [55]. In isolated systems, aluminum potentiates the oxidative 
stress  produced  by  iron  [56,57].  In  the  presence  of  aluminum,  iron  is  capable  of  enhanced  ROS 
formation  in  protein-free  liposomes  with  a  negative  charge  on  their  outer  surface.  Thus,  the 
electrostatic attraction of cations to the surface negative charge may play a role in metal-induced 
potentiation of ROS [58]. Both aluminum and β-amyloid peptides are not intrinsically pro-oxidant but 
share a similarity in their ability to stabilize iron in the ferrous form and thus enhance the Fenton 
reaction [59]. The ability of Fe and Cu to promote oxidative events based on their redox valence 
fluctuation  seems  to  be  intensified  by  their  incomplete  sequestration.  Particulates  and  colloidal 
compounds may partially complex pro-oxidant metals, and thus allow them to participate in Fenton 
reactions for a prolonged period [60,61]. The free radical generating potency of the Fenton reaction is 
increased by two orders of magnitude when the iron is complexed on nanoparticle surfaces [62]. 
The importance of particulate-metal interactions is evident in the case of asbestos. Amosite asbestos 
that appears to be free of iron, can promote ROS production but this is prevented in the presence of an 
iron chelator [63]. This illustrates that very low amounts of metals with redox potential, bound to 
particulate surfaces, can initiate ROS generation. Aggregated β-amyloid peptides and high molecular 
weight aluminum matrices are likely to have a extensive solid/liquid interface surface area that could 
present an appropriate site for transition metal absorption and activation leading to an increased rate of 
generation of reactive oxygen species. Aβ-generated hydroxyl radical formation may be mediated by 
the reduction of Fe and Cu [64] and aluminum could act in a parallel manner [59]. Aluminum may also 
catalyze  the  formation  of,  and  co-deposit  together  with,  amyloid  peptides,  forming  redox-active  
metal-complexed β-sheets [65]. 
It  has  been  suggested  that  many  age-related  neurological  diseases  involve  distortion  of  metal 
homeostasis.  For  example  the  binding  of  synuclein  to  transition  metals  alters  its  structure  and 
aggregation  propensity  [66].  Excess  copper  and  iron  ingestion  may  accelerate  age-related  loss  of 
cognition  [67].  As  a  result,  metal  chelation  has  been  suggested  as  a  potential  therapy  for 
neurodegenerative disease [68,69].  
5. Summary 
There is a remarkable convergence of pathways activated in several neurodegenerative diseases and 
those activated within the brain by colloidal or particulate material of exogenous origin. While the sites 
of damage and types of aggregate involved can vary widely, the sequence of events triggered by their 
chronic presence with the brain has an extraordinary commonality. The existence of a broad range of 
severe neurological disorders of genetic origin, involving the accumulation of complex carbohydrates 
and lipids, such as galactosidoses and sphingolipidoses, further points to the inability of the brain to 
tolerate the prolonged accrual of insoluble materials.  
The growing exposure of the population to nanoparticles from a variety of sources is a cause for 
concern. The major route of contact with such materials is not by way of inhalation of ambient air and 
fumes, but increasingly by the use of nanoparticles in consumer products, food additives and medical 
drugs. The cumulative effects of these exposures are unknown. Int. J. Environ. Res. Public Health 2011, 8                 
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The ability of colloids and nanoparticles to initiate inflammatory events within the brain may be 
based on interactions between two factors: 
1.  Although particulate inclusions may be chemically inert, if they are a critical size, they can 
lead  to  the  initiation  of  immune  responses  from  glial  cells.  Microglia  are 
immunocompetent  and  can  be  provoked  into  assuming  phagocytic  characteristics 
reminiscent of those of neutrophils and macrophages of non-nervous tissues [30]. As in 
the periphery, when such responses fail to clear the initiating material, this can lead to 
recruitment of more immune active cells and consequent increase of inflammatory activity. 
This cooperative interaction is a very effective antibacterial strategy but such uncontrolled 
innate immune responses and excessive production of inflammatory cytokines within the 
central  nervous  system  (CNS)  can  be  deleterious  [70].  Infiltration  of  peripheral 
macrophages into the brain may further exacerbate such events [71]. 
2.  The large surface area of very small particles can serve as an attractant of metal ions. 
When these include transition metals capable of expressing more than one valence state 
under physiological conditions (Fe, Cu, Mn), this forms an effective platform for Fenton-
like cycling activity leading to production of reactive oxygen species [72]. It is significant 
that the ability of asbestos to induce oxidative damage to DNA can be suppressed by 
desferal, a potent iron chelator [73]. Thus the iron-sequestering capacity of this particulate 
plays an important role in determining its overall toxicity. 
These factors could explain why a large variety of unrelated materials that are not truly soluble and 
are chemically rather inert, seem to be implicated in slow-progressing neurodegenerative disorders. 
There  may  thus  be  a  link  between  diseases  involving  the  progressive  accretion  of  endogenous 
macromolecules  in  an  insoluble  form,  and  nature  of  the  CNS  damage  effected  by  xenobiotic 
particulates of exogenous origin. 
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